(Sharecast News) - Pharmaceutical and medical tech group Johnson & Johnson raised its 2026 outlook on Tuesday after first-quarter results marginally beat Wall Street estimates on the back of strong growth from its oncology drug portfolio.
The company is now guiding to full-year sales of $100.3bn-101.3bn, raising its January estimate by...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE